Enhertu: payments to doctors
Payments that named Enhertu as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $20.8M
- Providers
- 19,434
- Transactions
- 131,429
- Average per transaction
- $158
The per-transaction average — $158 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 19,434 providers the average total is $1,070, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Daiichi Sankyo Inc. | $13,638,057 | 65.6% |
| AstraZeneca | $6,659,895 | 32.0% |
| Astrazeneca UK Limited | $259,759 | 1.2% |
| Daiichi Sankyo Company LTD | $218,486 | 1.1% |
| Daiichi Sankyo Europe GmbH | $20,758 | 0.1% |